BRNS - Company ID 0001828185
The table below shows Barinthus Biotherapeutics plc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$3.37M | -$14.90M | -$11.82M | -$3.17M | -$6.58M | -$7.97M |
| Capital expenditure | $0.00 | $5.00K | $308.00K | $2.51M | $1.09M | $392.00K |
| Investing cash flow | $55.00K | -$5.00K | -$308.00K | -$2.51M | -$1.09M | -$392.00K |
| Dividends paid | - | - | - |
Barinthus Biotherapeutics plc. reported operating cash flow of -$47.98M for fiscal year 2025. That is down 65.8% from -$28.94M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from -$11.03M (FY 2020) to -$47.98M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $0.00 | $2.00K | $503.00K | $1.69M | -$159.00K | $121.81M |